Amphotericin B nephrotoxicity: an update;Néphrotoxicité de l'amphotéricine B : mise au point

Journal de Mycologie Medicale

Volumn 16, Issue 2, 2006, Pages 82-86

  Deroure, B ^a   Charpentier, B ^a   Saliba, F ^b   Durrbach A ^a  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Acute renal failure; Amphotericin B; Fungal infections; Immunodepression; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ACUTE KIDNEY FAILURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; KIDNEY TUBULE DISORDER; MYCOSIS; NEPHROTOXICITY; NONHUMAN; RENAL ARTERY; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SODIUM DEPLETION; VASOCONSTRICTION;

EID: 33745834690     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mycmed.2006.05.001     Document Type: Short Survey

References (25)

1. Alexander B.D., and Wingard J.R. Study of renal safety in amphotericin B lipid complex-treated patients. Clin. Infect. Dis. 40 (2005) S414-S421
2. Antoniadou A., and Dupont B. Lipid formulations of amphotericin B: where are we to day. J. Mycol. Med. 15 (2005) 230-238
3. Barton C.H., Pahl M., Vaziri N.D., and Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am. J. Med. 77 (1984) 471-474
4. Bates D.W., Su L., Yu D.T., Chertow G.M., Seger D.L., Gomes D.R., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32 (2001) 686-693
5. Brezis M., Rosen S., Silva P., Spokes K., and Epstein F.H. Polyene toxicity in renal medulla: injury mediated by transport activity. Science 224 (1984) 66-68
6. Cheng J.T., Witty R.T., Robinson R.R., and Yarger W.E. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int. 22 (1982) 626-633
7. Chuck S.L., and Sande M.A. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Med. 321 (1989) 794-799
8. Fisher M.A., Talbot G.H., Maislin G., McKeon B.P., Tynan K.P., Strom B.L., et al. Risk factors for Amphotericin B-associated nephrotoxicity. Am. J. Med. 87 (1989) 547-552
9. Harbarth S., Pestotnik S.L., Lloyd J.F., Burke J.P., and Samore M.H. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am. J. Med. 111 (2001) 528-534
10. Heidemann H.T., Gerkens J.F., Spickard W.A., Jackson E.K., and Branch R.A. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am. J. Med. 75 (1983) 476-481
11. Heyman S.N., Clark B.A., Kaiser N., Epstein F.H., Spokes K., Rosen S., et al. In-vivo and in-vitro studies on the effect of amphotericin B on endothelin release. J. Antimicrob. Chemother. 29 (1992) 69-77
12. Heyman S.N., Stillman I.E., Brezis M., Epstein F.H., Spokes K., and Rosen S. Chronic amphotericin nephropathy: morphometric, electron microscopic, and functional studies. J. Am. Soc. Nephrol. 4 (1993) 69-80
13. Ito J.I., and Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin. Infect. Dis. 40 (2005) S384-S391
14. Johnson P.C., Wheat L.J., Cloud G.A., Goldman M., Lancaster D., Bamberger D.M., et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 137 (2002) 105-109
15. McCurdy D.K., Frederic M., and Elkinton J.R. Renal tubular acidosis due to amphotericin B. N. Engl. J. Med. 278 (1968) 124-130
16. McKinsey D.S., Gupta M.R., Riddler S.A., Driks M.R., Smith D.L., and Kurtin P.J. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 111 (1989) 655-659
17. Mishra M., Biswas U.K., Jha A.M., and Khan A.B. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 344 (1994) 1599-1600
18. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., van der Horst C.M., Edwards J.E., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331 (1994) 1325-1330
19. Sawaya B.P., Briggs J.P., and Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. 6 (1995) 154-164
20. Sawaya B.P., Weihprecht H., Campbell W.R., Lorenz J.N., Webb R.C., Briggs J.P., et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J. Clin. Invest. 87 (1991) 2097-2107
21. Sharkey P.K., Graybill J.R., Johnson E.S., Hausrath S.G., Pollard R.B., Kolokathis A., et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22 (1996) 315-321
22. Walev I., and Bhakdi S. Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob. Agents Chemother. 40 (1996) 1116-1120
23. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340 (1999) 764-771
24. Wingard J.R., Kubilis P., Lee L., Yee G., White M., Walshe L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29 (1999) 1402-1407
25. Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., and Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31 (2000) 1155-1163